SCORPION THERAPEUTICS TEAMS WITH WESTWOOD & WILSHIRE TO FILL SENIOR DIRECTOR OF TARGET BIOLOGY ROLE

South San Francisco, April 4— Scorpion Therapeutics, a Boston-based oncology focused precision medicine company, has brought in Hsu-Ping (Sunny) Kuo as Senior Director, Target Biology. The hire follows an impressive $162 million Series B for the company, which plans on pursuing several of its own therapeutics in the coming months.

Dr. Kuo joins Scorpion from AbbVie, where she has been promoted multiple times over the past seven years, most recently to her role as Principal Scientist II. Dr. Kuo’s expertise has long been in cancer, working intensively with lymphoma at AbbVie, and previously completing two postdocs-- one at the MD Anderson Cancer Center and one studying leukemias at Stanford University. She received her Ph.D. in Oncology and Cancer Biology from the University of Texas Health Science Center, and her M.S. from the National Taiwan University. Dr. Kuo has over 25 publications and 6 registered patents or patent applications.

The search was successfully led by Khusbu Talati for Westwood & Wilshire’s Life Sciences Practice.

Westwood & Wilshire is a retained executive search firm that recognizes people as any organization’s top asset. The firm has delivered premier talent to many of the world’s most innovative companies in life sciences, healthcare, and advanced technology. Westwood & Wilshire specializes in bringing top-tier candidates at the mid-management to C-Suite level to clients ranging from VC backed start-ups to mid-sized commercial entities. The firm has offices in Los Angeles, Silicon Valley, Scottsdale, and Connecticut serving clients worldwide.